Peli BioThermal brings Credo on Demand to Toronto

0
283


Peli BioThermal has partnered with ATS Healthcare to bring its Credo on Demand rental programme to Canada, with its first drop point in the country.

Located at the ATS Healthcare headquarters in Toronto, the drop point serves the further expansion of Peli BioThermal’s Credo on Demand rental programme by providing an additional point of return for reusable shipping assets.

ATS Healthcare is also a distributor for Peli BioThermal products throughout Canada.

Peli BioThermal vice president of Credo on Demand, Dominic Hyde says: “The Canadian pharmaceutical market is already the 10th-largest in the world and is forecasted to grow into a $25 billion industry by 2021.

“Our Credo rental programmes provide customers with a cost-effective way of quickly expanding container fleets based on demand, without adding to overhead costs. Additional drop points, like that being offered at ATS Healthcare in Toronto, add further flexibility.”

ATS Healthcare is the largest provider in Canada’s temperature controlled healthcare transportation industry, and the Toronto drop point offers both Peli and ATS customers an additional option for returning Credo on Demand assets at the end of the rental period, including Credo Xtreme pallet shippers and Credo Cargo bulk shippers.

ATS Healthcare COO, Bob Brogan says: “In our experience, the Credo on Demand rental programme provides the best range of temperature controlled passive shipper rental and leasing options.

“With so many of our customers already using Credo shippers to protect payloads with critical temperature requirements, we’re confident the addition of this drop point will allow us to better serve customers who are looking to improve payload volume efficiency and lower distribution costs.”

Peli is expanding the number of network stations acting as the origin point for new assets and act as end of rental drop-off points, as well as the number of drop points.

The Toronto drop point is one of more than 50 new drop points planned for 2018, including eight in the US and 13 across Europe already announced.